Upon joining the study, the patient is randomly assigned to one of three groups. Each group receives a different treatment: ofatumumab, siponimod, or fingolimod.

An initial assessment is conducted to evaluate the patient’s health status and confirm eligibility based on criteria such as age, diagnosis of multiple sclerosis, and previous medical history.

The patient begins the treatment phase, which lasts for up to two years.

If assigned to the ofatumumab group, the patient receives the medication via subcutaneous injection. The dosage and frequency are determined by the study protocol.

If assigned to the siponimod group, the patient takes the medication orally in the form of film-coated tablets. The dosage and frequency are determined by the study protocol.

If assigned to the fingolimod group, the patient takes the medication orally in the form of film-coated tablets. The dosage and frequency are determined by the study protocol.

Throughout the treatment phase, the patient’s health is regularly monitored through various assessments.

These assessments include measuring the annualized relapse rate, conducting MRI scans to check for new or enlarging lesions, and evaluating neurofilament light chain concentration in the blood.

Additional tests may include checking for anti-ofatumumab antibodies, monitoring for any adverse events, and conducting routine health checks such as ECGs, laboratory tests, and pulmonary function tests.

After completing the initial two-year treatment phase, the patient may enter an open-label extension phase.

During this phase, the patient continues to receive treatment, and further monitoring and assessments are conducted to gather additional data on the long-term effects and safety of the medications.